Responding to a potentially disruptive technology: How big pharma embraced biotechnology

Julian Birkinshaw, I. Visnjic, Simon Best

Producción científica: Artículo en revista indizadaArtículorevisión exhaustiva

16 Citas (Scopus)

Resumen

How do incumbent firms respond over time to a potentially disruptive technology? This article documents the strategies of 12 large pharmaceutical firms over 25 years as they addressed the opportunity/threat of biotechnology. All showed awareness of biotechnology’s potential, but their response profiles varied dramatically in terms of timing (early/late) and focus (external/internal). Late movers mostly made large acquisitions to “catch up,” but early movers maintained their lead in terms of biotechnology-based drug sales and profitability, and those with a more “open” response profile performed better. This response involves a three-step process: building awareness (sensing), building capability (responding), and building commitment (scaling).

Idioma originalInglés
Páginas (desde-hasta)74-100
Número de páginas27
PublicaciónCalifornia Management Review
Volumen60
N.º4
DOI
EstadoPublicada - 1 ago 2018
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Responding to a potentially disruptive technology: How big pharma embraced biotechnology'. En conjunto forman una huella única.

Citar esto